What is the recommended pharmacologic treatment regimen for glaucoma?

Glaucoma Drug Treatment

Prostaglandin analogs (latanoprost, bimatoprost, travoprost, or tafluprost) are the first-line pharmacologic treatment for glaucoma, administered once daily at bedtime. 1, 2

Initial Medical Therapy

The American Academy of Ophthalmology's 2021 Preferred Practice Pattern establishes prostaglandin analogs as the preferred initial therapy because they:

• Provide the most effective IOP reduction (20-30% reduction) 3
• Require only once-daily dosing (improving adherence)
• Are the best tolerated glaucoma medication class
• Have the most favorable side effect profile 1, 2

Start with a single prostaglandin analog unless contraindications exist (pregnancy, active uveitis, cystoid macular edema risk, or patient refusal due to cosmetic concerns about periorbital changes). 1

Treatment Algorithm When Prostaglandins Are Insufficient

If target IOP is not achieved with prostaglandin monotherapy:

1. First, verify the patient is actually using the medication correctly - nearly 45% of patients take fewer than 75% of prescribed doses 4

2. Add (don't switch) a second agent from a different class:

   • Beta-blockers (timolol, betaxolol): 15-25% IOP reduction, dosed once or twice daily

     • Avoid nighttime dosing - associated with limited efficacy and may worsen visual field progression via nocturnal hypotension 1
     • Contraindicated in asthma/COPD, bradycardia, heart block

   • Alpha-2 agonists (brimonidine): 15-20% IOP reduction

     • Useful as adjunctive therapy
     • Avoid in patients taking MAO inhibitors

   • Topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide): 15-20% IOP reduction

     • Contraindicated in sulfonamide allergy
     • Consider fixed combinations to improve adherence 4

3. If two medications fail, add a third agent from the remaining classes before considering oral carbonic anhydrase inhibitors

4. Oral carbonic anhydrase inhibitors (acetazolamide, methazolamide): 20-30% IOP reduction

   • Reserved for refractory cases or acute IOP elevation
   • Significant systemic side effects (electrolyte imbalance, kidney stones, blood dyscrasias)
   • Contraindicated in sulfonamide allergy, kidney stones, aplastic anemia, sickle cell disease 1

Target IOP

Set target IOP at 20% below baseline mean IOP for glaucoma suspects, though this may be insufficient if baseline pressure is markedly elevated. 1 Reassess and lower target if optic nerve or visual field deterioration occurs despite treatment.

Critical Pitfalls to Avoid

• Do not continue a medication that produces no IOP response - switch rather than add 2
• Do not use monocular trials to assess medication efficacy - they are unreliable due to asymmetric IOP fluctuations and contralateral effects 4
• Do not dose beta-blockers at night - this reduces efficacy and may accelerate visual field loss 1
• Do not overlook adherence issues - address at every visit through patient education, simplified regimens, and cost considerations 4

Alternative and Adjunctive Options

Rho kinase inhibitors (netarsudil): 10-20% IOP reduction, newer class with unique mechanism (increases trabecular outflow, decreases episcleral venous pressure). Common side effect is conjunctival hyperemia. 1

Parasympathomimetics (pilocarpine): Rarely used due to side effects and dosing frequency, reserved for specific situations.

Evidence Quality Note

Network meta-analysis confirms prostaglandin analogs provide superior IOP lowering compared to all other monotherapy options 3, supporting their position as first-line therapy. The 2021 AAO guidelines represent the most current, high-quality evidence for glaucoma pharmacotherapy. 1